

ASX Release 11th April 2017

ASX code: PIQ

Research Report and Investor Briefing

MedTech company Proteomics International Laboratories Ltd (PILL, ASX: PIQ) is pleased to advise that Independent Investment Research has initiated coverage on PILL.

To view a copy of the research report, please visit the company's website: www.proteomicsinternational.com/investors/stock-information/

PILL managing director Dr Richard Lipscombe will be showcasing the company and PromarkerD, the world leading predictive diagnostic test for diabetic kidney disease, at Investor Briefings as part of Proactive's CEO Spotlight Investor Session in Melbourne today, and in Sydney on Wednesday 12th April.

The Investor Presentation is available for download from the Newsroom at: www.proteomicsinternational.com

For further information please contact:

Dr Richard Lipscombe

Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com

Greg Wood [Financial Advisor]
Managing Director
K S Capital
T: +61 416 076 377
E: g.wood@kscapital.com.au

www.proteomicsinternational.com

Susan Fitzpatrick-Napier [Media Contact]

Digital Mantra Group T: +61 2 8218 2144 E: team@dmgpr.com

About Proteomics International Laboratories (PILL)

PILL is an ASX listed (ASX: PIQ) life science company focused on the area of proteomics – the industrial scale study of the structure and function of proteins. PILL is recognised as a global leader in the field of proteomics. It received the world's first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the art facilities located on the QEII Medical Campus in Perth, Western Australia. The Company's business model uses its proprietary technology platform across three integrated areas of diagnostics, drug discovery and analytical services.

Proteomics International Laboratories Ltd